Akums Acquires Oriflame India Manufacturing Assets in Rs 56 Crore CDMO Expansion

Akums Drugs and Pharmaceuticals' acquisition of Oriflame India's manufacturing business for Rs 56 crore signals a deliberate pivot by one of India's largest CDMOs into adjacent consumer health manufacturing, a move that broadens the facility's production scope and raises immediate questions around GMP harmonisation across product categories.

The acquisition coincides with a strong Q2 performance: revenue grew 32% year-on-year, EBITDA more than doubled, and net profit posted a 168% increase. For plant heads and QA directors, the financial headroom those numbers represent is material, it suggests Akums has the capital base to absorb integration costs, fund process validation for new product lines, and sustain compliance investment across an expanded manufacturing footprint.

The strategic logic is consistent with broader consolidation trends in India's CDMO sector, where contract manufacturers are increasingly acquiring distressed or divested assets to add capacity and diversify revenue beyond regulated-market pharmaceutical supply. Oriflame India's manufacturing operations, previously oriented toward personal care and wellness products, introduce a different regulatory framework alongside 21 CFR Part 211-adjacent GMP requirements, one that Akums' quality systems will need to accommodate without diluting existing pharmaceutical sterility assurance standards.

For regulatory affairs leads tracking India's CDMO landscape, the deal also reflects a wider pattern: as multinational consumer health brands rationalise owned manufacturing, Indian contract manufacturers are positioned to absorb those assets at scale. How Akums integrates Oriflame's quality infrastructure into its existing ICH Q10-aligned pharmaceutical quality system will be a practical test of that model's durability.

The measurable checkpoint ahead is how Akums reports segment-level margins from the acquired operations in subsequent quarters, which will indicate whether consumer health manufacturing delivers the EBITDA accretion the headline financials imply.

Source: Media4Growth via Indian Pharma Post, 2 November 2026.